These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 15739035

  • 1. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
    Palomba S, Orio F, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F.
    Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
    [Abstract] [Full Text] [Related]

  • 2. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes.
    Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V.
    Hum Reprod; 2003 Jan; 18(1):192-8. PubMed ID: 12525466
    [Abstract] [Full Text] [Related]

  • 3. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
    Creatsa M, Pliatsika P, Kaparos G, Antoniou A, Armeni E, Tsakonas E, Panoulis C, Alexandrou A, Dimitraki E, Christodoulakos G, Lambrinoudaki I.
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes.
    Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V.
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):365-71. PubMed ID: 12608943
    [Abstract] [Full Text] [Related]

  • 5. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Mar; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 7. Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
    Yoon BK, Lee DY, Park MC, Cho SH, Park HM, Choi YM.
    J Korean Med Sci; 2017 Jun; 32(6):992-998. PubMed ID: 28480658
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 9. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 10. Vitamin D receptor alleles, bone mineral density and turnover in postmenopausal osteoporotic and healthy women.
    Duman BS, Tanakol R, Erensoy N, Oztürk M, Yilmazer S.
    Med Princ Pract; 2004 Mar; 13(5):260-6. PubMed ID: 15316258
    [Abstract] [Full Text] [Related]

  • 11. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFELY Study.
    Garnero P, Borel O, Sornay-Rendu E, Arlot ME, Delmas PD.
    J Bone Miner Res; 1996 Jun; 11(6):827-34. PubMed ID: 8725180
    [Abstract] [Full Text] [Related]

  • 13. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
    Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH.
    Metabolism; 2006 Jun; 55(6):741-7. PubMed ID: 16713432
    [Abstract] [Full Text] [Related]

  • 14. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
    Mizunuma H, Shiraki M, Shintani M, Gorai I, Makita K, Itoga S, Mochizuki Y, Mogi H, Iwaoki Y, Kosha S, Yasui T, Ishihara O, Kurabayashi T, Kasuga Y, Hayashi K.
    J Bone Miner Metab; 2006 Aug; 24(1):11-5. PubMed ID: 16369892
    [Abstract] [Full Text] [Related]

  • 16. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW.
    Maturitas; 2001 Jul 25; 39(1):71-7. PubMed ID: 11451623
    [Abstract] [Full Text] [Related]

  • 17. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.
    J Bone Miner Res; 2013 Jun 25; 28(6):1328-36. PubMed ID: 23281041
    [Abstract] [Full Text] [Related]

  • 18. Association of transforming growth factor beta1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis.
    Yamada Y, Harada A, Hosoi T, Miyauchi A, Ikeda K, Ohta H, Shiraki M.
    J Bone Miner Res; 2000 Mar 25; 15(3):415-20. PubMed ID: 10750555
    [Abstract] [Full Text] [Related]

  • 19. Influence of the vitamin D receptor gene alleles on bone mineral density in postmenopausal and osteoporotic women.
    Vandevyver C, Wylin T, Cassiman JJ, Raus J, Geusens P.
    J Bone Miner Res; 1997 Feb 25; 12(2):241-7. PubMed ID: 9041056
    [Abstract] [Full Text] [Related]

  • 20. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun 25; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.